Retatrutide 10 mg: Research Guide, Mechanism & Specification

Retatrutide 10 mg is a triple-receptor agonist and one of the most closely watched compounds in current metabolic research. This guide explains what it is, how the three-receptor mechanism differs from single- and dual-agonist peptides, what published research reports, and how research-grade material should be specified, reconstituted and stored. Written for research context only – no human use protocols are provided.

What is Retatrutide?

Retatrutide (development code LY3437943) is a synthetic peptide engineered to activate three metabolic receptors simultaneously: the GLP-1 receptor, the GIP receptor and the glucagon receptor. It belongs to the incretin class, the same broad family as semaglutide and tirzepatide, but it is the first widely studied compound in that family to add glucagon receptor agonism to the mix.

The molecule is a 39-amino-acid peptide with a fatty acid side chain. That acylation is not cosmetic – it drives binding to serum albumin, which is what gives the compound its extended half-life and makes once-weekly dosing schedules feasible in study designs.

It is supplied as a lyophilized white powder in a sealed vial. The 10 mg presentation is the standard research format.

The triple-agonist mechanism

Each of the three receptors contributes something different, and the interest in Retatrutide comes from the combination rather than any single pathway:

• GLP-1 receptor — glucose-dependent insulin secretion, slowed gastric emptying, central satiety signalling
• GIP receptor — incretin signalling that complements GLP-1 and appears to improve tolerability of the combination
• Glucagon receptor — increased energy expenditure and hepatic lipid metabolism, the component absent from earlier incretin compounds

Why glucagon agonism is the interesting part

Glucagon is conventionally understood as the hormone that raises blood glucose, so adding a glucagon agonist to a glucose-lowering compound looks counterintuitive. The rationale in the literature is that glucagon receptor activation increases resting energy expenditure and drives hepatic fat oxidation, while the GLP-1 and GIP components offset the glycaemic effect. It is a balance-of-pathways design rather than a single-target one.

How it compares to GLP-1 and dual agonists

Placing Retatrutide next to the compounds researchers usually compare it with makes the distinction clearer.

Research overview

The table summarises the principal areas Retatrutide has been investigated in. These are observations from published literature, not outcomes to be expected outside a controlled research setting.

Context matters here. Retatrutide is an investigational compound that has not completed phase 3 evaluation and is not approved by the EMA or FDA for any indication. Reported effects come from controlled trial settings with medical supervision, and heart-rate increases and gastrointestinal effects are documented alongside the metabolic findings. Treating phase 2 data as settled science would be a mistake.

Retatrutide 10 mg specification

The Retatrutide supplied by Peptide Revolution is intended strictly for laboratory research. Each vial is documented so a study can be traced back to a specific batch.

Reconstitution & storage

Retatrutide is an acylated peptide, which makes it more robust than many unmodified sequences – but handling still determines whether a vial holds specification through a study.

• Lyophilized, frozen — stable long term at −20 °C in the sealed vial, protected from light
• Lyophilized, room temperature — tolerates shipping; refrigerate on arrival
• Reconstituted — store at 2–8 °C and use within the study window
• Diluent — bacteriostatic water is standard; add it slowly down the vial wall, never directly onto the powder
• Avoid — shaking, repeated freeze–thaw cycles and direct light; swirl gently to dissolve

For a compound with a completely different mechanism, see our BPC-157 10 mg research guide, or compare with the oral secretagogue in our MK-677 research guide.

Frequently asked questions

What is Retatrutide used for in research?

Published work investigates Retatrutide in metabolic research – body weight regulation, glycaemic markers, hepatic lipid content and energy expenditure. It is an investigational compound, not an approved treatment for any condition.

How does Retatrutide differ from tirzepatide?

Tirzepatide activates two receptors, GLP-1 and GIP. Retatrutide adds a third, the glucagon receptor, which is associated in the literature with increased energy expenditure and hepatic fat oxidation.

What purity should research-grade Retatrutide have?

≥99% by HPLC, confirmed on a certificate of analysis referencing the batch number printed on your vial. A generic COA not tied to your batch provides no real assurance.

How should Retatrutide 10 mg be stored?

Lyophilized vials keep long term at −20 °C, protected from light. After reconstitution with bacteriostatic water, store at 2–8 °C and avoid freeze–thaw cycles.

Is Retatrutide approved for human use?

No. Retatrutide is an investigational compound that has not completed phase 3 trials and is not approved by the EMA or FDA. It is supplied strictly for in-vitro laboratory research.

Why is Retatrutide supplied as a lyophilized powder?

Freeze-drying removes the water that drives peptide degradation, so the compound remains stable far longer in storage and transport than it would in solution. It is reconstituted only when a study requires it.

Research use disclaimer

All products supplied by Peptide Revolution are intended strictly for in-vitro laboratory research and analytical purposes. They are not medicinal products, food supplements, cosmetics or veterinary preparations, and they are not approved for the diagnosis, treatment or prevention of any condition.

By purchasing, the customer confirms they are a qualified professional or research institution and that the material will be handled in accordance with applicable laws and good laboratory practice. This article summarises published scientific literature for informational purposes and does not constitute medical advice or a usage recommendation.